Detection of Poor Mobilizer (PM) in Multiple Myeloma (MM) Patients

CompletedOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

November 26, 2015

Primary Completion Date

January 19, 2021

Study Completion Date

January 17, 2024

Conditions
Multiple Myeloma
Interventions
DRUG

Plerixafor

Plerixafor (AMD3100) is a selective, reversible inhibitor of the receptor chemokine (C-X-C motif) receptor 4 (CXCR4) and prevents binding of its cognate ligand stromal cell derived factor-1α (SDF-1α), also known as chemokine (C-X-C motif) ligand 12 (CXCL12) \[3\]. CXCR4 is a co-receptor, along with CD4, for the binding of human immunodeficiency virus, type 1 (HIV-1) to its receptor cells.

Trial Locations (1)

10126

A.O.U. Città della Salute e della Scienza di Torino, Torino

All Listed Sponsors
lead

Fondazione EMN Italy Onlus

OTHER

NCT03406091 - Detection of Poor Mobilizer (PM) in Multiple Myeloma (MM) Patients | Biotech Hunter | Biotech Hunter